Cargando…
Single and Multiple Dose Pharmacokinetics, Pharmacodynamics and Safety of the Novel Lipoprotein-Associated Phospholipase A(2) Enzyme Inhibitor Darapladib in Healthy Chinese Subjects: An Open Label Phase-1 Clinical Trial
BACKGROUND AND OBJECTIVES: Darapladib is a lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) inhibitor. This study evaluated the pharmacokinetics, pharmacodynamics and safety of darapladib in healthy Chinese subjects. METHODS: Twenty-four subjects received darapladib 160 mg orally, approximately...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4605839/ https://www.ncbi.nlm.nih.gov/pubmed/26465780 http://dx.doi.org/10.1371/journal.pone.0139862 |